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Despite advances in treatment and outcomes for patients with
pediatric acute lymphoblastic leukemia (ALL), there continue to
be subsets of patients who are refractory to standard
chemotherapy and hematopoietic stem cell transplant. There-
fore, novel gene targets for therapy are needed to further
advance treatment for this disease. RNA interference technol-
ogy has identiﬁed survivin as a potential therapeutic target.
Survivin, a member of the inhibitor of apoptosis (IAP) proteins
and chromosome passenger complex, is expressed in hemato-
logic malignancies and overexpressed in relapsed pediatric
ALL. Our studies show that survivin is uniformly expressed at
high levels in multiple pediatric ALL cell lines. Furthermore,
silencing of survivin expression in pediatric ALL cell lines as
well as primary leukemic blasts reduces viability of these cells.
This includes cell lines derived from patients with relapsed
disease featuring cytogenetic anomalies such as t(12;21),
Philadelphia chromosome t(9;22), t(1;19) as well as a cell line
carrying t(17;19) from a patient with de novo ALL. Furthermore,
inhibition of survivin increases p53-dependent apoptosis that
can be rescued by inhibition of p53. Finally, a screen of
randomly selected primary patient samples conﬁrms that
survivin-speciﬁc small interfering RNA and survivin-targeted
drug, YM155, effectively reduce viability of leukemic blasts.
Leukemia (2012) 26, 623–632; doi:10.1038/leu.2011.249;
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Introduction
Over the past 50 years, the prognosis for pediatric acute
lymphoblastic leukemia (ALL) has changed from a terminal
diagnosis to a treatable disease.
1 The success of current
therapeutic regimens has given rise to the identiﬁcation of a
subset of patients who will have recurrent or refractory disease.
Unfortunately, patients within these subsets have highly resistant
disease that may not be overcome even with myeloablative
therapy and hematopoietic stem cell transplant. These diseases
may have approached the limit of treatment by standard
chemotherapeutic regimens. Therefore, new targets for therapy
are imperative in the hope of improving outcomes.
A report from the Children’s Oncology Group has shown a
differential expression proﬁle of relapsed ALL compared with
initial diagnosis.
2 One of the genes showing a marked increase
in expression in patients with recurrent disease is survivin (aka
BIRC5). Survivin is an attractive target for therapy because it is
expressed mainly during development and in the setting of
malignancy with little to no expression in normal terminally
differentiated tissue. Furthermore, survivin overexpression has
correlated with resistant and refractory disease in many different
malignancies including ALL.
3
Survivin is a small 16kD protein that belongs to the inhibitor
of apoptosis (IAP) family and also functions as a member of the
chromosome passenger complex. Survivin is a unique member
of the IAPs in that it is both the smallest member and may not
directly interact with caspases. Instead, it may interact with
another IAP, smac/Diablo, to regulate apoptosis within the
mitochondria.
4 Transcription of survivin shows several splice
variants with conserved N-terminal domains, with most of the
divergence occurring within or after the baculovirus IAP repeat
domain.
5–7 Recent published reports would suggest that these
splice variants may have different subcellular localization
including the mitochondria and different apoptotic activities.
8
The role of survivin as a member of the chromosome
passenger complex, in which it plays a critical role during
mitosis, is better deﬁned.
9 As such, survivin expression is cell-
cycle dependent, with the highest expression during G2/M
through canonical cell cycle-dependent and cell-cycle homol-
ogy regions within the proximal promoter.
10 During mitosis,
survivin speciﬁcally localizes with INCENP and Aurora B kinase
within the mitotic apparatus from the centromeres in prophase,
kinetochores in metaphase, the mid-plate during anaphase and
the mid-body during cytokinesis. Furthermore, it is the direct
interaction of survivin with both Aurora B kinase and INCENP
that is essential for cell division.
11–13 Survivin phosphorylation
at Ser 20 by PLK1 (polo-like kinase) is required for the priming of
Aurora B kinase activity to undergo cell division.
14
In this study we veriﬁed the cell-cycle dependence of survivin
expression within pediatric ALL cells. We further tested whether
several pediatric leukemic cell lines as well as primary patient
samples were sensitive to manipulation of survivin expression
and activity. Pediatric ALL cell lines have similar expression
levels of total survivin. In addition, the expression patterns of
survivin among cell lines were similar with an increase in
survivin expression during G2/M. Virtually all of the ALL cell
lines tested were sensitive to silencing of survivin including REH
(ETV6-RUNX1), SUPB15 (BCR-ABL) RCH-ACV (E2A-PBX1) and
HAL01 (E2A-HLF). We also identiﬁed that targeting survivin
either by small interfering RNA (siRNA) or by the survivin-
suppressor YM155 in these cell lines increased cell death
through the p53-dependent apoptosis pathway. This increase in
cell death could then be rescued by silencing p53. Finally, early
screening of patient samples with survivin siRNA or YM155
showed sample-speciﬁc variation of sensitivity to survivin
silencing. The heterogeneity of YM155 responses would suggest
that other factors may have importance for primary lympho-
blasts to respond to survivin inhibition beyond p53. As such,
early disease selection through in vitro screening may become
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www.nature.com/leuimportant for future clinical strategies that would employ
survivin as a therapeutic gene target.
Materials and methods
Reagents
Fetal bovine serum (FBS) was obtained from Hyclone Laboratories
Inc. (South Logan, UT, USA). All other tissue culture reagents
were obtained from Invitrogen Corporation (Carlsbad, CA, USA).
The siRNAs (Supplementary Table 1) were from the siGenome
SMARTpool designed by Dharmacon (ThermoFisher Scientiﬁc,
Waltham, MA, USA). Viability assays were performed with
CellTiter 96 AQueous One Solution Cell Proliferation Assay from
Promega Corporation (Madison, WI, USA). Apoptosis assays were
performed using the Guava Nexin Assay (Millipore, Billerica, MA,
USA). YM155 was purchased from Selleck (Houston, TX, USA)
and solubilized in dimethylsulfoxide at 100mM stock. Graphical
and statistical data were generated using either Microsoft Excel or
GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA).
Cell lines and tissue culture
RCH-ACV (RCH) (Deutsche Sammlung von Mikroorganismen
und Zellkulturen GmbH (DSMZ), Braunschweig, Germany) is a
pediatric ALL cell line from a patient with recurrent disease
carrying the E2A-PBX1 t(1;19) chimeric protein. REH (ATCC) is a
pediatric ALL cell line from a patient with recurrent disease
carrying the ETV6-RUNX1 t(12;21) chimeric protein. SUPB15
(American Type Culture Collection (ATCC), Manassas, VA, USA)
is a pediatric ALL cell line also from a patient with recurrent
disease carrying the BCR-ABL t(9;22) translocation. HAL01 cells
(DSMZ) are from a pediatric patient with de novo ALL with the
E2A-HLF t(17;19). RCH, REH and HAL01 cells were maintained
in RPMI with 10% FBS, 4mM glutamine and 1% penicillin and
streptomycin. SUPB15 cells were maintained in RPMI with 20%
FBS, 4mM glutamine, 50nM 2-mercaptoethanol and 1%
penicillin and streptomycin. All patient samples were obtained
with informed consent approved by the institutional review
board of Oregon Health and Science University.
Small interfering RNA knockdown, proliferation and
induction of apoptosis
Standard electroporation was modiﬁed from a previously described
protocol.
15 Brieﬂy, 1.5 10
5 cells per condition were resuspended
in 75ml siPORT buffer (Applied Biosystems, Life Technologies
Corporation, Carlsbad, CA, USA). To the samples, 1–2mM of siRNA
was added. Cells were electroporated at 200V, 250ms, 2 pulses,
and 20000 cells per well were plated in triplicate containing
100ml of culture media. The remaining 60000 cells were plated
into a well containing 500ml of culture media. For determination
of cell viability, the triplicate plates containing 20000 cells were
subjected to the CellTiter 96 AQueous One Solution Cell Prolifera-
tion Assay (MTS). For subsequent immunoblot analysis, the plate
containing 60000 cells were harvested and lysed in 20mlo f1 
sodium dodecyl sulfate (SDS) loading buffer. Identiﬁcation of
induction of apoptosis was performed using the Guava Nexin assay
(Millipore). Brieﬂy, triplicate samples containing 20000 cells were
incubated with 60ml of the Guava Nexin reagent and then
analyzed through the microcapillary ﬂow cytometer at varying
time points up to 96h.
Cells were also treated with transductin (Integrated DNA
Technologies (IDT), Inc., Coralville, IA, USA) for introduction of
siRNA into the cells. A total of 500nM of siRNA was incubated in
phosphate buffered saline (PBS) with 5mM transductin and added to
2.5 10
5 cells in 0.5ml of RPMI with 1% bovine serum albumin for
2–4h at 371C. The cell media was then supplemented with 0.5ml
of RPMI containing FBS such that the ﬁnal concentration of FBS was
10–20% (depending on cell line). A total of 50000 cells per well
were plated in triplicate and grown for 4 days for either MTS or for
Gauva Nexin assay. The remaining cells were harvested 48h after
treatment for immunoblot.
Immunoblot analysis
Cells were washed with PBS and lysed with 1  SDS loading buffer
(75mM T r i s ,p H6 . 8 ,3 %S D S ,1 5 %g l y c e r o l ,8 %b-mercaptoetha-
nol, 0.1% bromophenol blue). For mitochondrial fractionation, cells
were processed using ApoALert Cell Fractionation Kit (Clontech,
Mountain View, CA, USA). All samples were separated by standard
SDS-polyacrylamide gel electrophoresis and transferred onto poly-
vinylidene ﬂuoride membrane (Immobilon-FL, Millipore). Mem-
branes were blocked with Aquablock tm/EIA/WB (EastCoast Bio,
Inc., North Berwick, ME, USA) for 1h, and then incubated with
primary antibodies to survivin (Cell Signaling Technology, Inc.,
Danvers, MA, USA), (Ser 10) phospho-histone H3 (Upstate
Biotechnology, Lake Placid, NY, USA), tubulin (Sigma-Aldrich
Corp., St Louis, MO, USA), (Ser 15) phospho-p53 (Cell Signaling),
p53 (Santa Cruz, Biotechnology, Inc., Santa Cruz, CA, USA) and
ABL (BD Biosciences, San Jose, CA, USA) in Aquablock/0.1%
Tween-20 overnight at 41C. Secondary ﬂuorescent antibodies
(Molecular Probes) were used and detected and quantiﬁed with
Odyssey (LI-COR, Corporate Ofﬁces, Lincoln, NE, USA).
Immunoﬂuorescence
ALL cells were grown in complete media and then B5 10
5
cells were harvested and resuspended in 0.5ml of PBS. 2 10
4
cells were spotted onto a cover slip for 10min. Cells were ﬁxed
with 4% formaldehyde at 371C for 10min. Samples were then
permeabilized with 0.25% Triton X-100 and washed with PBS.
Cells were then stained overnight in 41C with primary
antibodies and subsequently stained for 1h with secondary
antibody at room temperature. All images were captured with
an Olympus (San Jose, CA, USA) BX Fluorescent Microscope
using a  50–100 objective, automatic ﬁlter-wheel and Cytovi-
sion workstation.
Cell sorting
ALL cell lines were grown in RPMI/10% FBS to a concentration
of 5–10 10
5cells/ml. Cells were then washed with PBS/1%
FBS and ﬁxed in 70% ethanol and stored at  201C. The samples
were then washed with PBS and stained with buffer containing
3mM EDTA, pH 8.0, 0.05% NP-40, 50mg/ml propidium iodide
and 1mg/ml RNAse A in PBS.
16 Cells were sorted by DNA
content with BD FACS/Aria (BD Biosciences) and harvested with
SDS loading buffer.
YM155 dose response
ALL cells lines (5000 cells per well) and primary patient samples
(50000 cells per well) were incubated with graded concentra-
tions of YM155 (0–10mM) in RPMI with 10% FBS. After 3 days,
cells were subjected to MTS for assessment of cell viability.
All values were normalized to the no drug control from each
respective cell line.
Results
Pediatric ALL cell lines express high levels of survivin
mostly at G2/M
Prior studies have suggested that there are varying amounts of
survivin expression in primary pediatric ALL samples and in
p53, apoptosis, survivin, acute lymphoblastic leukemia
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Leukemiapediatric ALL cell lines.
2,17 To validate this ﬁnding, we assessed
survivin expression level in a variety of cell lines derived from
divergent subsets of pediatric ALL patients, including HAL01
cells that have been used to describe the dependence of survivin
overexpression through the chimeric transcription factor
E2A-HLF found in t(17;19).
17 Immunoblot of a population of
asynchronous cells showed varying amounts of survivin
when normalized to tubulin expression, with SUPB15 cells
showing a statistically signiﬁcant difference to REH (t-test 0.04;
Figures 1a and c).
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Figure 1 Relative expression of survivin in ALL cell lines and cell-cycle dependence. (a) Immunoblot of asynchronous populations ALL cell lines
for survivin, (Ser 10) phospho-histone H3 (pH3) and tubulin. The cell lines tested include REH (ETV6-RUNX1), RCH-ACV (E2A-PBX1), HAL01
(E2A-HLF) and SUPB15 (BCR-ABL). The immunoblot shown is representative of three independent experiments. (b) Survivin level is dependent on
the cell cycle in ALL cell lines. An asynchronous population of ALL cell lines was ﬁxed in 70% ethanol and stained with propidium iodide. Cells
were ﬂow sorted by DNA content for G1, early S (S1), late S (S2) and G2/M. Top panels represent the histograms of the cells that were sorted.
Bottom panels represent the immunoblots for survivin, pH3 and tubulin. (c) Quantiﬁcation of survivin expression in relation to tubulin and pH3.
(Left panel) Each band from immunoblots was quantiﬁed by Odyssey for ﬂuorescence intensity and normalized either to tubulin for pH3. Ratios
were then compared with REH as control. (Right panel) Graphical representation of the relative quantity of survivin normalized to tubulin from
(b). Quantity is expressed in comparison with REH in G1. *Denotes Po0.05 by student’s t-test. (d) Subcellular localization of survivin in
lymphoblasts. (Upper panel) Each cell line showed similar staining patterns. Representative images of later interphase, prophase, metaphase and
telophase are shown from each cell line. 5 10
5 cells of an asynchronous population were dropped onto coverslips and ﬁxed with formaldehyde,
and processed for dual immunoﬂuorescence labeling; survivin (green), pH3 (red), DAPI (blue). (Lower panel). Immunoblot of survivin and
cytochrome c after fractionation with Apoalert Fractionation. C, cytosolic fraction; M, mitochondrial fraction.
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LeukemiaSurvivin expression is regulated by the cell cycle and plays a
role within the chromosome passenger complex.
11–13 These
chromosome passenger complex proteins show relatively lower
expression in G1/S phase with the highest expression in G2/M.
To determine whether the small variations of survivin expression
observed in cell lines is dependent on the proportion of cells in
G2/M phase at the time of cell lysis, we also examined cell
lysates for abundance of Ser 10 phosphorylation on histone H3
(pH3), a marker for G2/M phase. After normalization of survivin
expression to pH3, there appeared to be no signiﬁcant
difference in the amount of survivin expression between cell
lines (Figures 1a and c). Furthermore, most of the expressed
survivin appears to be in G2/M as shown by ﬂow sorting cells
from different stages of the cell cycle followed by immunoblot
for survivin, pH3 and tubulin (Figures 1b and c).
The cell cycle-dependent expression of survivin would
suggest that in ALL cells lines the major role of survivin would
be as a member of the chromosome passenger complex.
However, survivin has been shown to exhibit divergent
subcellular localizations with certain splice variants exhibiting
cytosolic and mitochondrial distribution, suggesting that survi-
vin may also play a role as an IAP.
18 As such, we next wanted to
assess whether there are different subcellular pools of survivin
within ALL cell lines. We examined survivin expression patterns
in RCH, REH, SUPB15 and HAL01 cells by immunoﬂuores-
cence. In each cell line, the majority of survivin staining was
evident in cells undergoing mitosis (Figure 1d and data not
shown). There is an increase in survivin staining in early
prophase with evident colocalization with chromosomal mate-
rial, and there is a subsequent increase in the intensity of
survivin staining through metaphase. As the chromosomes
segregate, survivin stays at the mid-body through cytokinesis.
These results are consistent with prior published data on the
subcellular localization of survivin in monolayer cells.
8,11
Interestingly, we do observe some variation in punctate
cytosolic staining for survivin in interphase cells. The antibody
to survivin, which is generated against the N-terminus of the
protein (Cell Signaling), is predicted to react to all splice
variants. Furthermore, cell fractionation does show that there is
a small population of survivin in both the cytosolic and
mitochondrial fractions (Figure 1d).
Inhibition of survivin expression reduces cell viability in
ALL cell lines
As ALL cell lines appear to express similar amounts of survivin,
we next tested whether survivin knockdown would have
deleterious effects on viability of these cells. Leukemia cell
lines treated with survivin-speciﬁc siRNA consistently showed a
signiﬁcant reduction in viability, with RCH, REH, SUPB15 and
HAL01 cells each exhibiting at least 40% decrease in cell
viability (Figure 2a). Immunoblots performed 48h after siRNA
treatment conﬁrmed siRNA-mediated silencing of survivin of
B50% reduction in levels (Figure 2b and data not shown).
Recently, a novel small-molecule inhibitor, YM155, was
developed by Astellas Pharma US, Inc. (Deerﬁeld, IL, USA) as a
potent inhibitor of survivin expression.
19 This compound was
developed using a screen that identiﬁed small molecules that
would only inhibit survivin expression at the promoter. As this
reagent offered a different mode of survivin suppression, we also
tested the impact of this compound on viability of ALL cell lines.
Consistent with siRNA results, each of the cell lines tested
showed a dose-dependent sensitivity to YM155 as measured by
cell viability 72h after exposure (Figure 2c). Furthermore,
inhibition of survivin expression and increase in apoptosis can
be seen in a dose-dependent manner even at 24h after exposure
to YM155 (Supplementary Figure 1). To test whether YM155
sensitivity was speciﬁc to inhibition of survivin expression, RCH
cells were transfected with pMIG-Survivin. Cells were treated
with 1mM YM155 for 48h, and then assayed for apoptosis by
Annexin V staining. Ectopic expression of survivin in RCH cells
partially rescues apoptosis when treated with 1mM YM155,
further validating the selective inhibition of survivin (Supple-
mentary Figure 1d). Interestingly, there was some variation of
sensitivity to this compound with REH cells being the most
sensitive (half-maximal inhibitory concentration (IC50)1 7 n M)
and HAL01 showing the least sensitivity (IC50 560nM). RCH and
SUPB15 cells had IC50’s that ranged between 10 and 50nM.
These results would suggest a possible heterogeneity of response
among ALL lymphoblasts to inhibition of survivin.
Survivin inhibits the p53-dependent apoptotic pathway
in ALL cell lines
Previous studies have suggested that overexpression of survivin
inhibits the p53-dependent apoptosis pathway.
20 Therefore,
inhibition of survivin may allow for re-activation of this p53-
mediated apoptotic program. Prior data suggest that most pediatric
ALL cell lines are wild type for TP53 by gene expression
patterns.
21,22 To test whether the cells lines evaluated in this
study had an intact p53-dependent cell-cycle arrest, the cells were
treated with 0.1mg/ml of doxorubicin. Doxorubicin is an
anthracycline that is known to inhibit resealing of DNA breaks,
thereby activating a p53-dependent cell-cycle arrest and apoptosis
through the intrinsic pathway. RCH, REH, SUP B15 and HAL01
cells all showed activation of p53 by phosphorylation at Ser 15
(pTP53) within 4h of treatment (Figure 3a). Furthermore, these
cells showed cell-cycle arrest by decrease in pH3.
To test whether the increase in cell death observed after
silencing of survivin in ALL cell lines was due to p53 activity,
RCH and REH cells were treated with a combination of survivin
and p53 siRNA. As previously shown, knockdown of survivin
signiﬁcantly decreased the viability and increased annexin V
staining of both RCH and REH cells. Interestingly, treatment
with a combination of siRNA to p53 and survivin partially
rescued cell viability and decreased annexin V staining
(Figure 3b). Immunoblots performed showed similar amounts
of protein silencing (Figure 3c), whether alone or in combina-
tion. Interestingly, treatment of cells with siRNA to survivin
increases the quantity of p53 within the cell (Figure 3c). This
increase in p53 is also abrogated by siRNA to p53, suggesting
that this phenomenon is from increased transcription or stability
of the p53 transcript rather than enhanced stability of the p53
protein. These results are consistent with prior ﬁndings that
inhibition of survivin expression increases p53-dependent
apoptosis and may begin to shed new light as to the mechanism
of this inhibition.
23 Prior studies have shown conﬂicting data as
to whether survivin interacts with or is independent of
caspases.
17,24,25 For example, Nakahara et al.
19 have shown
that caspase 3 is activated by YM155 in HRPC cells whereas
Okuya et al.
17 describe caspase-independent cell death in
t(17;19) ALL. Our studies would further agree with Okuya
et al.
17 that neither caspase 3 nor caspase 9 is activated when
treated with either siRNA or YM155, yet they still activate
apoptosis in ALL cells (Supplementary Figures 1 and 2).
PhþALL cells are sensitive to knockdown of survivin
independent of imatinib
As previously discussed, PhþALL (BCR-ABL) is a model of
resistant disease in which the primary oncogene is well
p53, apoptosis, survivin, acute lymphoblastic leukemia
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Leukemiacharacterized. Although the addition of imatinib as targeted
therapy has improved outcome, there remain patients who
continue to relapse. To test whether PhþALL would also be
sensitive to targeting of survivin, SUPB15 cells were treated with
siRNA to survivin, BCR-ABL (ABL),and p53 (Figure 4). Knock-
down of survivin increases Annexin V staining that is then
rescued by siRNA to p53 (Figures 4a and b). Silencing of
survivin or BCR-ABL decreased cell viability by B50%
(Figure 4c). Furthermore, simultaneous knockdown of BCR-
ABL and p53 had a minimal effect on the cells, suggesting that
cell death after silencing of BCR-ABL occurs mainly through a
p53-independent mechanism.
Interestingly, the combination of survivin and BCR-ABL
silencing did not show an additive effect. It has previously been
shown that in certain CML cell lines, the BCR-ABL/mitogen-
activated protein kinase pathway increases expression of survivin
and that silencing of survivin enhances imatinib-induced cell
death.
26 To test whether survivin knockdown could also enhance
imatinib-induced cell death, SUPB15 cells were treated with
siRNA for survivin and p53 in the presence of 500nM imatinib
(Figure 4d). In contrast to cells treated with ABL siRNA where no
additivity with survivin was observed, knockdown of survivin did
show an additive increase in cell death in the presence of
imatinib. One possibility for this difference could involve minor
variations in signaling that occur after elimination of BCR-ABL
protein from cells (siRNA) versus inhibition of BCR-ABL activity
without eliminating the protein (imatinib). Another possibility
could include inhibition of other non-BCR-ABL pathways by
imatinib that could synergize with silencing of survivin. Knock-
down of p53 did not rescue the effects on cell viability of either
imatinib or ABL siRNA. In contrast, silencing of p53 did rescue
the effects of both survivin siRNA and YM155 (Figure 4d, lower
panel), and YM155 appears to activate p53 (Supplementary
Figure 1a). Cumulatively, these results support the role of survivin
as an inhibitor of p53-dependent apoptosis in PhþALL, which is
a pathway independent of BCR-ABL function, suggesting that
targeting of survivin could enhance therapy by inhibiting
independent pathways to imatinib.
Figure 2 Inhibition of survivin expression inhibits cell viability for REH, RCH, SUPB15 and HAL01. (a) Cell viability as measured by MTS 96h
after treatment with siRNA for survivin. All samples were treated with nonspeciﬁc (NS) siRNA as a control and normalized to 100%. s.e.m. bars are
inserted. *Po0.05, **Po0.01. (b) Representative immunoblots for the expression level of survivin treated with NS siRNA or survivin siRNA.
Tubulin expression was used as a control for loading. (c) Dose response of ALL cell lines to YM155. Asynchronous populations of cells were treated
with increasing doses of YM155 for 72h. Then, viability was measured by MTS and normalized to no drug control. S.e.m. bars are inserted. Dotted
line represents 50% viability.
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LeukemiaPrimary patient samples are sensitive to inhibition of
survivin
Our results would suggest that patients with pediatric ALL could
beneﬁt from inhibition of survivin. For initial, preclinical
validation of this strategy, we isolated leukemic blasts from
fresh primary ALL samples and treated the cells with siRNA to
survivin. Treatment of two, randomly selected primary patient
samples with survivin siRNA showed response with a 30–50%
decrease in cell viability (Figure 5a). To further validate survivin
as a bona ﬁde therapeutic target, we treated fresh primary
patient samples with YM155. Treatment of four patient samples
revealed a range of sensitivity to this drug from IC50 values
p10nM to IC50’s exceeding 1mM consistent with the cell lines
(Figure 5b). Interestingly, the samples that showed the highest
IC50’s were the HAL01 cells and the patient sample with
E2A-HLF. Immunoblots were also performed to identify the
expression levels of survivin as compared with tubulin and pH3
(Figures 5c and d). There was a distribution of variability of
expression that does not appear to correlate with sensitivity to
YM155. For example, patient 5 (relapsed with ETV6-RUNX1)
was most sensitive to YM155, yet had one of the lowest levels of
survivin expression when normalized to tubulin. However, this
patient had relatively high expression when normalized to pH3.
This would suggest that the cell cycle-independent expression of
survivin is a more important correlate for YM155 sensitivity than
overall survivin expression. In contrast, samples with E2A-HLF
(patient 3, Figure 5, and HAL01, Figure 2) exhibited less
sensitivity to YM155 despite high expression of survivin,
suggesting that other factors may play an important role in
YM155 sensitivity. E2A-HLF cell lines have previously been
Figure 3 Knockdown of p53 rescues cell death because of silencing of survivin. (a) Activation of p53 by treatment with doxorubicin. 1 10
6 cells
of RCH, REH, SUPB15 and HAL01 were treated with 0.1mg/ml of doxorubicin (Sigma) for 0, 4 and 8h. The cells were then harvested, separated
and immunoblotted for (Ser 15)-phospho-p53 (pp53), pH3 and tubulin. S15P p53 evaluated the phosphorylation state of p53 at Ser 15 by activation
of the replication checkpoint. pH3 was again used as a marker for cell-cycle arrest reﬂecting a decrease in the number of cells entering mitosis.
(b) Partial rescue of cell viability by knockdown of p53. RCH and REH cells were treated with siRNA to NS, survivin, p53 and a combination of
p53/survivin. Viability was tested by MTS and normalized to NS (left panel). Apoptosis was then evaluated by Annexin V binding (right panel).
(c) Immunoblots of representative duplicate experiments to quantify the expression of survivin, and p53 after treatment with siRNA. Lower panels
show the relative expression normalized to tubulin quantiﬁed by ﬂuorescence intensity.
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Leukemiashown to overexpress the drug efﬂux protein ABCB1,
27 which
may reduce the amount of YM155 within the cell, thereby
increasing the IC50. These studies would suggest that preselec-
tion of patients by in vitro screening for sensitivity to YM155
would be important in future studies using this compound for
clinical trials.
Discussion
In contrast to prior reports, our data have shown that ALL cell
lines express similar amounts of survivin and that most of the
protein is expressed during G2/M. Meanwhile, primary patient
samples do show signiﬁcant variability in survivin expression.
This study also demonstrates that knockdown of survivin in ALL
increases p53-dependent apoptosis. Furthermore, in the BCR-
ABL line SUPB15, reduction of BCR-ABL activity or expression
does not increase the p53-dependent apoptotic pathway.
Finally, we show that screening of primary samples with either
siRNA to survivin or the selective suppressor YM155 has the
potential to identify samples that are more sensitive to survivin
inhibition.
There is evidence to support the interaction of survivin with
the p53-dependent apoptotic pathway. In BaF3 cells, it has been
shown that overexpression of survivin has the ability to inhibit
degradation of Mdm2 (murine double minute 2), thereby
promoting degradation of p53.
28 Other studies have shown that
p53 has the ability to decrease survivin expression.
20 In human
lung and ovarian cancer cell lines, activation of p53 decreases
expression of survivin by changing acetylation of the survivin
promoter rather than direct binding. In our studies, silencing of
survivin did show a qualitative increase in p53 expression.
These ﬁndings would suggest that there is a critical relationship
with survivin and p53 whereby higher levels of survivin inhibit
p53 either by degradation or inhibition of expression, whereas
inhibition of survivin activates p53 and increases p53 expres-
sion. Taken together, our studies support the critical role for the
interaction of survivin with the p53-dependent apoptotic path-
way as an important regulator of growth in pediatric lympho-
blasts.
Molecular targeting of survivin continues to be an intriguing
concept for therapy. It is a protein whose expression is almost
exclusively conﬁned to dividing cells such as malignant tissue
and normal hematopoietic stem cells and colonic epithe-
lium.
29,30 Although survivin is expressed differentially within
the cell cycle with the highest expression at G2/M, some studies
have suggested a baseline increase in expression in malignant
cells.
31 Also, higher expression of survivin has been shown in
BCR-Abl
Survivin
p53
Tubulin
7
-
A
A
D
100
100
101
101
102
102
103
103
104
104
100
100
101
101
102
102
103
103
104
104
100
100
101
101
102
102
103
103
104
104
100
100
101
101
102
102
103
103
104
104
Annexin V-PE
NS p53
survivin p53/survivin
41% 30%
55% 35%
70
60
50
P
e
r
c
e
n
t
 
a
n
n
e
x
i
n
 
V
 
s
t
a
i
n
i
n
g
40
30
20
10
140
120
100
80
60
40
20
0
P
e
r
c
e
n
t
 
v
i
a
b
i
l
i
t
y
140
160
120
100
80
60
40
20
NS NS/100nM
YM155
p53 p53/100nM
YM155
0
P
e
r
c
e
n
t
 
v
i
a
b
i
l
i
t
y
120
100
80
60
40
20
0
P
e
r
c
e
n
t
 
v
i
a
b
l
e
NS
NS
NS
SUR
SUR
SUR
ABL
ABL
ABL/SUR
p53/SUR ABL/SUR
p53
p53
p53/SUR
p53/ABL
p53/SUR
Control
500nM
imatinib
0
p53
Figure 4 Sensitivity of inhibition of survivin in SUPB15 cells is dependent on intact p53. (a) Flow cytometric representation of apoptosis by
staining for Annexin V and 7-aminoactinomycin D (7-AAD). SUPB15 cells (BCR-ABL) were treated with siRNA to NS, SUR, p53 and p53/SUR.
(b) A graphical representation of Annexin V staining in SUPB15 treated with NS, survivin, ABL, ABL/survivin, p53 and p53/survivin. (c) Graphical
representation of the percent viability of SUPB15 cells treated with NS, survivin, p53 and p53/survivin. The lower panel represents the
immunoblots performed on the samples treated with the siRNA and stained for BCR-ABL, survivin, p53 and tubulin. Viability was tested by MTS
and normalized to nonspeciﬁc siRNA (NS). (d) Treatment of SUPB15 cells with imatinib or YM155. Top panel shows cells treated with siRNA in
the presence of 500nM imatinib. Cells were treated with siRNA, and then subsequently incubated in 500nM imatinib for 96h. Bottom panel shows
the partial rescue of SUPB15 cells treated with 100nM YM155 for 96h. S.e.m. bars are inserted into each graph.
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Leukemiarecurrent and relapsed disease.
3 Furthermore, in cell lines there
does appear to be a weak but direct correlation with the quantity
of survivin expression and sensitivity to YM155.
32 Our studies
would suggest that there is a distribution of expression of
survivin in primary patient samples and the expression level may
not correlate with sensitivity to targeting of survivin.
There are many ways of targeting survivin such as antisense
oligonucleotides, ribozymes, siRNA, dominant-negative mu-
tants, small-molecule antagonists and immunotherapy.
33 Many
of these compounds are in early clinical phase I and II trials.
Interestingly, most of these compounds are well tolerated with
minimal toxicities and appear to have modest effects on heavily
pretreated patients when administered as monotherapy. Our
studies would suggest that pediatric ALL patients will also
beneﬁt from inhibition of survivin. Future studies are currently
under development for combination of these survivin-targeted
agents with other therapeutics.
In our studies we chose to utilize YM155 because this drug
has the advantage over siRNA or antisense oligos in that it does
not require a speciﬁc delivery system. When the drug is given as
a continuous intravenous infusion for 7 days, it was well
tolerated and also had modest effects on the diseases, including
diffuse large B-cell lymphomas.
32 Our studies would suggest
that speciﬁc patient samples or disease subtypes may respond
differently to these drugs. Therefore, selection of patients based
on in vitro sensitivity screens may improve response rates to this
and other survivin-targeted compounds.
Clearly, there are a variety of potential mechanisms that may
explain the heterogeneous responses observed to inhibition of
survivin. As knockout studies have conﬁrmed survivin as an
essential protein and it is also expressed in all cells undergoing
mitosis (including normal hematopoietic cells),
29 one could
argue that complete inhibition of survivin as a therapy may have
increased side effects because of its essential role within the cell.
Instead, perhaps selective inhibition of survivin as an IAP may
provide a better therapy. Our data, which were largely collected
using siRNA in which only partial silencing of survivin was
achieved, may suggest that a therapeutic strategy that also
achieved only partial inhibition of survivin could increase
p53-dependent apoptosis in a select group of pediatric ALL
including PhþALL. Therefore, partial inhibition of survivin may
have a selective role in adjuvant therapy for these diseases. In
contrast, cell line studies using YM155 have not shown a
correlation with sensitivity to survivin inhibition and p53 status.
19,32
These observations would suggest that other mechanisms must be
involved regarding inhibition of survivin and cell death.
Future studies must be performed to address several unan-
swered questions. The ﬁrst is the mechanism by which survivin
inhibits the p53-dependent apoptotic pathway in leukemic cells.
Previous data in t(17;19) cell lines would suggest that survivin
sensitivity is mediated through a mechanism independent of
caspases 3 and 9. Yet, we have observed that both the cell line
HAL01 and the primary t(17;19) patient sample were relatively
insensitive to YM155. This may suggest that there are other
mechanisms involved in this disease as opposed to the other
samples such as drug efﬂux. Another concern would be the
relative utility of targeting survivin in pediatric patients with
ALL. Our data would suggest that there may be a selective
population that is more sensitive to inhibition of survivin.
Currently, there are clinical trials using antisense oligonucleo-
tides (EZN-3042) to survivin either under development or in
phase I trials for relapsed leukemias. Our prediction would be a
Figure 5 Primary patient (Pat.) samples show sensitivity to inhibition of survivin. See Supplementary Table 2 for patient details. (a) Two random
fresh primary patient samples were treated with siRNA to NS and survivin. Viability was then assayed 4 days later by MTS, and normalized to
viability to NS. (b) Dose response of patient samples to YM155. Fresh mononuclear cells were separated by Ficoll and B50000 cells were plated
into each well containing increasing concentrations of YM155 from 1nM to 1mM. Viability was assayed 3 days later by MTS and normalized to no
drug control. Viability was then assayed 3 days later by MTS. All plots contain s.e.m. bars. (c) Immunoblots of patient samples for survivin pH3 and
tubulin. Approximately 1 10
7 cells were lysed in 100ml of SDS loading buffer and 20ml was run on polyacrylamide gel electrophoresis (PAGE).
(d) Graphical representation of survivin expression normalized to either tubulin or pH3 intensity. These ratios were then compared with REH ratios
as a control.
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Leukemiaheterogeneous response in these trials as only a subset of
patients within each disease subtype would be predicted to
exhibit survivin sensitivity, based on our ﬁndings. Furthermore,
our studies show the importance of preselection of subjects by
in vitro inhibitory screens to identify subjects more likely to
respond to survivin inhibition. Therefore, we would propose to
perform in vitro screening to assist with subject selection.
In conclusion, our data support the concept that targeting
survivin may be of clinical beneﬁt in pediatric ALL. Further-
more, this targeting would be selective to the role of survivin as
an IAP as opposed to its fundamental role in the chromosome
passenger complex. Future studies will be needed to verify these
results in primary patient samples and to identify patients who
will respond to therapies targeting survivin.
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